 Marker Therapeutics, Inc. Nasdaq: MRKR, a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport. The facility will allow production according to U.S. Food and Drug Administration FDA guidelines and is designed to be scalable using modular processes. The facility is expected to be completed by year-end and operational in 2021. 